TTM
-250.1%
YoY change
+90.07pp
Trough year (2022)
-469.7%
Peak year (2020)
900.8%
Latest annual
-224.3%
FCF Margin history chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: -224.3%
FCF Margin change chart for Tango Therapeutics (TNGX) from 2019 to 2025
Latest: +90.07pp
FCF Margin history table for Tango Therapeutics (TNGX) from 2019 to 2025
| 2025 | -224.3% | +90.07pp | ||
| 2024 | -314.4% | +12.80pp | ||
| 2023 | -327.2% | +142.54pp | ||
| 2022 | -469.7% | -304.06pp | ||
| 2021 | -165.7% | -1066.50pp | ||
| 2020 | 900.8% | +1008.83pp | ||
| 2019 | -108.0% | — |
- 2025-224.3%+90.07pp
- 2024-314.4%+12.80pp
- 2023-327.2%+142.54pp
- 2022-469.7%-304.06pp
- 2021-165.7%-1066.50pp
- 2020900.8%+1008.83pp
- 2019-108.0%—
FCF Margin values are taken from Tango Therapeutics's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About FCF Margin at Tango Therapeutics (TNGX)
According to Tango Therapeutics's latest reported financial statements, the company's latest reported free cash flow margin is -250.1%. Free cash flow margin is free cash flow divided by revenue — the share of each sales dollar that converts into cash after capital expenditures. Because free cash flow cannot be inflated by non-cash accounting, FCF margin is a clean read on how efficiently a business turns revenue into deployable cash.
Headline figure above is from the reporting period ending (reported ). Chart and table below cover the full reported history back to .
2025's annual free cash flow margin for Tango Therapeutics (TNGX) came in at -224.31% – expanded 90.1 percentage points year-over-year.
The record annual free cash flow margin stands at 900.84%, reached in 2020; the historical low of -469.72% was recorded in 2022.
Tango Therapeutics FCF Margin by Year
Tango Therapeutics FCF Margin 2025: -224.3%
2025's free cash flow margin for Tango Therapeutics came in at -224.31%, expanded 90.1 percentage points from 2024.
Tango Therapeutics FCF Margin 2024: -314.4%
Tango Therapeutics posted free cash flow margin of -314.38% in 2024, expanded 12.8 percentage points from 2023.
Tango Therapeutics FCF Margin 2023: -327.2%
In 2023, Tango Therapeutics reported free cash flow margin of -327.18%, expanded 142.5 percentage points from 2022.
Tango Therapeutics FCF Margin 2022: -469.7%
Tango Therapeutics free cash flow margin in 2022 was -469.72%, contracted 304.1 percentage points from 2021. This figure represents the lowest annual value in the available history.
Tango Therapeutics FCF Margin 2021: -165.7%
Tango Therapeutics free cash flow margin in 2021 was -165.66%.
See more financial history for Tango Therapeutics (TNGX).
Sector peers by FCF Margin
Healthcare peers of Tango Therapeutics (TNGX), ranked by their latest free cash flow margin
| 33.2% | |
| 23.1% | |
| 21.5% | |
| 18.8% | |
| 18.4% | |
| 15.1% | |
| 9.4% | |
| 4.4% |
- 33.2%
- 23.1%
- 21.5%
- 18.8%
- 15.1%
Frequently asked questions
Tango Therapeutics (TNGX) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation